People with arm access for dialysis face a tough choice. They need their access to stay open, yet they also need to avoid dangerous bleeding. A new look at data from 1,265 adults helps clarify this balance. The research focused on those getting systemic heparin, a common blood thinner, compared to standard care without it.
The findings offer a clear trade-off. Using systemic heparin significantly reduced the odds of early patency loss, meaning the access stayed open better in the early days. However, this benefit came with a cost. The risk of bleeding complications went up for those receiving the treatment.
This does not mean doctors should stop using heparin. It suggests that using it as a preventive strategy requires weighing the clot risk against the bleeding risk for each individual patient. Surgeons and care teams must consider these surgical factors and the specific needs of every person before deciding on this approach.
